Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the research and development team will present the clinical design for an ongoing study of VS-6063 and preclinical data on the dual PI3K/mTOR inhibitor VS-5584 at the American Society of Clinical ... (more)
http://technews.tmcnet.com/news/2013/05/23/7156502.htm
http://technews.tmcnet.com/news/2013/05/23/7156502.htm
No comments:
Post a Comment